Shot: Santhera has discontinued the development of Puldysa (idebenone) in patients with DMD who are in respiratory decline and receive concomitant glucocorticoid treatment. The DSMB has recommended the discontinuation of […]readmore
Tags : Idebenone
Shots: The SYROS study involves assessing of respiratory function evolution during periods of treatment with idebenone (900 mg/day) (On-Idebenone) compared to period without idebenone treatment (Off-Idebenone) in 18 patients with […]readmore
Shots: The MAA submission follows the results of P-II DELPHI study, DELPHI-Extension study, P-III DELOS (1-5) study and SYROS study. The collective studies result demonstrated that Puldysa (idebenone) is showing […]readmore
Shots: The P-III DELOS trial involves assessing of idebenone (900mg/day) vs PBO in 64 patients with DML for 52 wks. P-III DELOS study results: 50% reduction in annual rates of […]readmore